The aim of the present single-center study was to compare the outcome following ASCT in myeloma and lymphoma patients who needed Plerixafor for a successful stem cell mobilization procedure with the outcome in those myeloma and lymphoma patients who were successfully mobilized with G-CSF alone during the same time period. The gene discussed is CSF3; the disease is lymphoma.